USA: The STRIDE trial has demonstrated that semaglutide significantly enhances walking capacity in individuals with ...

For patients with symptomatic peripheral artery disease and type 2 diabetes, semaglutide use is associated with increased ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

CHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

The treatment of many patients with peripheral artery disease is not optimal, and indeed is much worse than that in patients ...

PAD is considered the first and most frequent manifestation of cardiovascular disease in patients with diabetes. There are few therapeutic and interventional options for patients ...

Novo Nordisk's Phase 3b STRIDE trial shows Ozempic improves walking distance in peripheral artery disease, while the SOUL ...

If you have been feeling too many cramps in your legs, along with cold feet and numbness, it could be due to high cholesterol ...

High cholesterol, or hypercholesterolemia, usually has no apparent symptoms and is therefore labeled as a "silent killer." ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million ...